☆ 4.5 Editorial Material

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Related references

Note: Only part of the references are listed.

Review Biotechnology & Applied Microbiology

Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan

Julia E. McGuinness et al.

Summary: SG, LV, and T-DXd have shown potential to significantly improve clinical outcomes in pretreated mTNBC patients, with notable response rates in phase I/II and phase III clinical trials. Investigation into their use in combination with other agents is ongoing, and their application in early-stage TNBCs is being explored. ADCs are anticipated to redefine treatment approaches in TNBC.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders

Vishal M. Gohil

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Review Oncology

Unlocking the potential of antibody-drug conjugates for cancer therapy

Joshua Z. Drago et al.

Summary: Nine ADCs are currently approved for cancer treatment, with many more in development. Advances in synthetic biochemistry have led to a new generation of ADCs promising improved tissue specificity and cytotoxicity. Despite impressive activity against treatment-refractory cancers, challenges such as systemic toxicity and acquired resistance remain. This review discusses the design, mechanism of action, and limitations of ADCs, proposing strategies to maximize their therapeutic benefit for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Chemistry, Medicinal

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive

Dey Nandini et al.

Summary: Metastatic triple-negative breast cancer is a unique and complex form of breast cancer with high rates of relapse and distant metastasis. Chemotherapy is crucial for managing this subtype and preventing disease recurrence for long-term survival. New agents such as eribulin, PARP inhibitors, and ADCs targeting TROP2 are approved for the management of this disease.

PHARMACEUTICALS (2021)

Add to Collection

Meeting Abstract Oncology

Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer

M. Tsai et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Emanuela Ferraro et al.

Summary: The development of new generation HER2-targeted ADCs has transformed the treatment of HER2-positive breast cancer and re-energized drug development. These agents not only show great efficacy in traditional HER2-positive breast cancer, but also have the potential to be clinically valuable in cells with low HER2 expression or ERBB2 mutations.

BREAST CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer

Elia Cipriano et al.

Summary: Metastatic triple-negative breast cancer is a heterogeneous disease with limited treatment options, but recent approvals of targeted drugs for specific patient populations show promise. Various combinations of targeted treatments are being investigated in clinical trials, with potentially practice-changing results on the horizon.

BREAST CANCER-BASIC AND CLINICAL RESEARCH (2021)

Add to Collection

Review Chemistry, Multidisciplinary

Metformin and cancer immunity

Ruixia Ma et al.

ACTA PHARMACOLOGICA SINICA (2020)

Add to Collection

Book Review Oncology

Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications

Karla A. Lee et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Review Oncology

Triple-negative breast cancer molecular subtyping and treatment progress

Li Yin et al.

BREAST CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Novel antibody-drug conjugates for triple negative breast cancer

Aiko Nagayama et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

Noam Ponde et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Mark L. Zangardi et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

Add to Collection

Meeting Abstract Oncology

Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor

Anthony T. Cao et al.

CANCER RESEARCH (2018)

Add to Collection

Review Pharmacology & Pharmacy

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Hashem O. Alsaab et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

Review Oncology

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Giampaolo Bianchini et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Add to Collection

Editorial Material Medicine, Research & Experimental

Cancer immunotherapy: harnessing the immune system to battle cancer

Yiping Yang

JOURNAL OF CLINICAL INVESTIGATION (2015)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.